Az infekciókontroll rendszerének sajátosságai az Egyesült Államokban
Cikk címe: Az infekciókontroll rendszerének sajátosságai az Egyesült Államokban
Szerzők: Dr. Kovács Ákos
Intézmények: DRC Balatonfüred Szent István és Szent László Kórház
Évfolyam: XV. évfolyam
Lapszám: 2016. / 10. lapszám
Oldal: 14-19
Rovat: INFEKCIÓKONTROLL
Alrovat: INFEKCIÓKONTROLL
Absztrakt:
Az Egyesült Államokban az infekció kontroll kórházi gyakorlatához számos tudományos és hatósági szervezet biztosítja az elvi alapokat, az elvárások meghatározását és a célok megvalósulásának értékelését, közzétételét. Sok évtizedes kutatómunka, a résztvevő szervezetek összehangolt, sokszor egymást kiegészítő strukturált tevékenysége csiszolta az infekció kontrollt és a vele szorosan összekapcsolódó infektológiai betegellátást meglehetősen magas színvonalúvá.
Az Egyesült Államokban összegyűlt tapasztalat, tudásanyag megszerzésével egy kis ország nem tud versenyezni, de a tudományos és gyakorlati eredmények hozzáférhetők és felhasználhatók Magyarország számára is.
Abstract:
Several scientific and administrative organizations in the USA provide the theoretical support, define expectations, control and publish results of accomplishment of infection control goals of hospitals. Infection control and the closely related infectious disease patient care has reached a fairly high standard in the US as a result of decades of research and coordinated and well structured efforts.
A small country like Hungary cannot compete with the abundance of experience, the body of knowledge that has piled up in the US but the results of science and experience are broadly available and can be followed with great benefit.
XV. évfolyam
2016. / 10. lapszám / December
| Szerző | Intézmény |
|---|---|
| Dr. Kovács Ákos | DRC Balatonfüred Szent István és Szent László Kórház |
[1] Magill SS, Edwards JR, Bamberg W, et al.: Multistate point-prevalence survey of health care-associated infections, N Engl J Med, 2014, 370:1198.
[2] Haley RW, Culver DH, White JW et al.: The nationwide infection rate: a new need for vital statistics, Am J Epidemiol, 1985, 121:159-167
[3] Jasny BR, Bloom FE: It’s not rocket science – but it can save lives, Science, 1998, 280:1507
[4] Marchetti A, Rossiter R: Economic burden of healthcare-associated infection in US acute care hospitals: societal perspective, J Med Econ, 2013, 16:1399.
[5] Climo MW, Yokoe DS, Warren DK, et al.: Effect of daily chlorhexidine bathing on hospital-acquired infection, N Engl J Med, 2013, 368:533.
[6] Haley RW, Culver DH, White JW, et al.: The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals, Am J Epidemiol, 1985, 121:182.
[7] Healthcare Infection Control Practices Advisory Committee, General guidelines, http://www.cdc.gov/hicpac/pubs.html (Accessed on October 01, 2014).
[8] Yokoe DS, Anderson DJ, Berenholtz SM, et al.: A compendium of strategies to prevent healthcare-associated infections in acute care hospitals: 2014 updates, Infect Control Hosp Epidemiol, 2014; 35:967.
[9] Wenzel RP: Organization for infection control. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 5th ed, Mandell GL, Bennett JE, Dolin R (Eds), Churchill Livingstone, Philadelphia 2000. p.2988.
[10] Weinstein RA, Siegel JD, Brennan PJ: Infection-control report cards–securing patient safety, N Engl J Med, 2005; 353:225.
[11] McKibben L, Horan T, Tokars JI, et al. : Guidance on public reporting of healthcare-associated infections: recommendations of the Healthcare Infection Control Practices Advisory Committee, Am J Infect Control, 2005, 33:217.
[12] Hospital-acquired infections: New York State 2011. New York State Department of Health, Albany, NY 2012.
[13] Department of Labor, Occupational Safety and Health Administration. Occupational exposure to bloodborne pathogens: final rule, Fed Reg, 1991, 56: 64175.
[14] Hoffmann KK: The modern infection control practicioner. In: Wenzel RP, ed. Prevention and Control of Nosocomial Infections, 3rd ed, Baltimore: Williams & Wilkins, 1997, 33-45
[15] O’Boyle C, Jackson M, Henly SJ: Staffing requirements for infection control programs in U.S. helath care facilities: Delphi project, Am J Infect Control, 2002, 30:321-333
[16] Friedman C, Chenoweth C: A survey of infection control professional staffing patterns at University Health System Consortium Institutions, Am J Infect Control, 1998, 26:239-244
[17] Scheckler WE, Brimhall D, Buck AS et al.: Requirements for infrastructure and essential activities of infection control and epidemiology in hospitals: a consensus panel report, Infect Control Hosp Epidemiol, 1998, 19:114-124
[18] Peterson LR, Hacek DM, Robicsek A: 5 Million Lives Campaign. Case study: an MRSA intervention at Evanston Northwestern Healthcare, Jt Comm J Qual Patient Saf, 2007, 33:732.
[19] Klevens RM, Morrison MA, Nadle J, et al. : Invasive methicillin-resistant Staphylococcus aureus infections in the United States, JAMA, 2007, 298:1763.
[20] Huskins WC, O’Grady NP, Samore M, et al.: Design and methodology of the Strategies to Reduce Transmission of Antimicrobial Resistant Bacteria in Intensive Care Units (STAR-ICU) trial, Infect Control Hosp Epidemiol, 2007, 28:245.
[21] Pittet D, Hugonnet S, Harbarth S, et al.: Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme, Lancet, 2000, 356:1307.
[22] Muto CA, Jernigan JA, Ostrowsky BE, et al.: SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus, Infect Control Hosp Epidemiol, 2003, 24:362.
[23] Harbarth S, Masuet-Aumatell C, Schrenzel J, et al.: Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study, Crit Care, 2006, 10:R25.
[24] Pan A, Carnevale G, Catenazzi P, et al.: Trends in met- hicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: effect of the MRSA “search and isolate” strategy in a hospital in Italy with hyperendemic MRSA, Infect Control Hosp Epidemiol, 2005, 26:127.
[25] Verhoef J, Beaujean D, Blok H, et al.: A Dutch approach to methicillin-resistant Staphylococcus aureus, Eur J Clin Microbiol Infect Dis, 1999, 18:461.
[26] Kluytmans-Vandenbergh MF, Kluytmans JA, Voss A.: Dutch guideline for preventing nosocomial transmission of highly resistant microorganisms (HRMO), Infection, 2005, 33:309.
[27] Harbarth S, Fankhauser C, Schrenzel J, et al.: Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients, JAMA, 2008, 299:1149.
[28] Robicsek A, Beaumont JL, Paule SM, et al.: Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals, Ann Intern Med, 2008, 148:409.
[29] Loeb MB, Main C, Eady A, Walker-Dilks C.: Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization, Cochrane Database Syst Rev, 2003, CD003340.
[30] Lee AS, Macedo-Vinas M, François P, et al.: Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistent methicillin-resistant Staphylo coccus aureus carriage after decolonization therapy: a case-control study, Clin Infect Dis, 2011, 52:1422.
[31] Calfee DP, Salgado CD, Milstone AM, et al.: Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute care hospitals: 2014 update, Infect Control Hosp Epidemiol ,2014, 35:772.
[32] Liu C, Bayer A, Cosgrove SE, et al.: Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children, Clin Infect Dis, 2011, 52:e18.
[33] http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ca_04mee-ting.html (Accessed on June 24, 2008)
[34] Simor AE, Phillips E, McGeer A, et al.: Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization, Clin Infect Dis, 2007, 44:178.
[35] Buehlmann M, Frei R, Fenner L, et al. : Highly effective regimen for decolonization of methicillin-resistant Staphy lococcus aureus carriers, Infect Control Hosp Epidemiol, 2008, 29:510.
[36] Sandri AM, Dalarosa MG, Ruschel de Alcantara L, et al.: Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA, Infect Control Hosp Epidemiol, 2006, 27:185.
[37] Fridkin SK, Welbel SF, Weinstein RA.: Magnitude and prevention of nosocomial infections in the intensive care unit, Infect Dis Clin North Am, 1997, 11:479.
[38] Vincent JL, Rello J, Marshall J, et al.: International study of the prevalence and outcomes of infection in intensive care units, JAMA, 2009, 302:2323.
[39] Kumar A, Roberts D, Wood KE, et al.: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock, Crit Care Med, 2006, 34:1589.
[40] Kollef MH, Fraser VJ: Antibiotic resistance in the intensive care unit, Ann Intern Med, 2001, 134:298.
[41] Dortch MJ, Fleming SB, Kauffmann RM, et al.: Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections, Surg Infect (Larchmt), 2011, 12:15.
[42] Ostrowsky BE, Trick WE, Sohn AH, et al.: Control of van-comycin-resistant enterococcus in health care facilities in a region, N Engl J Med, 2001, 344:1427.
[43] Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C: Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit, JAMA, 1999, 282:1745.
[44] Haley RW, Cushion NB, Tenover FC, et al.: Eradication of endemic methicillin-resistant Staphylococcus aureus infections from a neonatal intensive care unit, J Infect Dis, 1995, 171:614.
[45] Dembry LM, Uzokwe K, Zervos MJ: Control of endemic glycopeptide-resistant enterococci, Infect Control Hosp Epidemiol, 1996, 17:286.
[46] Jensen PA, Lambert LA, Iademarco MF, et al. 46. Guidelines for preventing the transmission of Myco bacterium tuberculosis in health-care settings, 2005, MMWR Recomm Rep, 2005, 54:1.